Post-transcriptional alterations in LDLR may potentially explain the lower number of functional LDLR and hence the higher circulating level of LDL-C in FH patients(7), and may also explain the similar baseline gene expression level of LDLR observed among subjects with and without FH in this study. The gene discussed is LDLR; the disease is familial hyperaldosteronism.